93366-88-2Relevant articles and documents
Design and evaluation of a potential mutagen for Hepatitis C virus
Koh, Yung-Hyo,Shim, Jae Hoon,Girardet, Jean-Luc,Hong, Zhi
, p. 5261 - 5264 (2007)
Pyrrolopyrimidine nucleoside 1 was designed and synthesized as a potential mutagen for HCV. An in vitro HCV NS5B enzymatic assay indicated that pyrrolopyrimidine triphosphate acts as a CTP analog rather than a UTP analog. The SATE-prodrug of pyrrolopyrimidine monophosphate showed a weak inhibitory activity in an HCV replicon system (EC50 = 60 μM) and did not exhibit cytotoxicity (CC50 > 100 μM). Investigation of phosphorylation events using nucleoside kinases and LC-MS analysis revealed that the second phosphorylation step, from monophosphate ester to diphosphate ester, is unfavorable.
COMPOUNDS FOR THE TREATMENT OF HIV
-
Page/Page column 325; 326, (2013/03/26)
The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.
CYTIDINE ANALOGS AND METHODS OF USE
-
Page/Page column 32, (2010/02/08)
Cytidine analogs, their prodrugs and/or metabolites are employed as pharmaceutically active compounds for treatment of diseases responsive to such compounds. Particularly preferred diseases include viral diseases (e.g., HCV infection) and neoplasms.